Takeaways from ASH 2023 in Higher-Risk MDS
Experts on myelodysplastic syndromes offer their key takeaways from the 2023 ASH Annual Meeting in the higher-risk disease space.
EP: 1.Diagnosis of Myelodysplastic Syndromes (MDS)
EP: 2.Risk Stratification of Myelodysplastic Syndromes
EP: 3.First-Line Treatment of Lower-Risk MDS with Symptomatic Anemia
EP: 4.Patient Profile 1: A 72-Year-Old Man With MDS
EP: 5.Second-Line Treatment of Lower-Risk MDS With Symptomatic Anemia
EP: 6.Patient Profile 2: A 77-Year-Old Man With MDS
EP: 7.Unmet Needs and Adverse Event Management for Patients With Lower-Risk MDS and Symptomatic Anemia
EP: 8.ESA Treatment Selection in MDS
EP: 9.Updates from COMMANDS Trial: Luspatercept in Lower-Risk MDS
EP: 10.Retrospective Claims Data and Patient Reported-Outcomes from COMMANDS Trial in Lower-Risk MDS
EP: 11.IMerge: Imetelstat in Patients With Lower-Risk MDS
EP: 12.Cytopenias Following Imetelstat Treatment in Lower-Risk MDS
EP: 13.Emerging Clinical Trials in MDS and Key Takeaways from ASH 2023
EP: 14.Treatment Options and Unmet Needs in Higher-Risk MDS
EP: 15.Updates from ASH 2023 in Higher-Risk MDS
Now Viewing
EP: 16.Takeaways from ASH 2023 in Higher-Risk MDS
EP: 17.Closing Thoughts on the MDS Treatment Landscape
Related Videos
Related Content
